Medical problems occurring during the long-term follow-up after liver transplantation

Swiss Surgery

Volumn 9, Issue 5, 2003, Pages 237-241

  Demirag, A ^a   Buhler L H ^a   Majno, P ^a   Berney, Th ^a   Chilcott, M ^a   Giostra, E ^b   Morel, Ph ^a   Mentha, G ^a  

^a University Hospitals   (Switzerland)

^b NONE   (Switzerland)

Author keywords

Liver transplantation; Long term patient survival; Medical complications

Indexed keywords

ARTICLE; DIABETES MELLITUS; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LIVER FAILURE; LIVER TRANSPLANTATION; LONG TERM CARE; METABOLIC BONE DISEASE; PATIENT CARE; SURVIVAL RATE;

EID: 0141920697     PISSN: 10239332     EISSN: None     Source Type: Journal    
DOI: 10.1024/1023-9332.9.5.237     Document Type: Article

References (43)

1. Smith CM, Davies DB, McBride MA. Liver transplantation in the United States: A report from the Organ Procurement and Transplantation Network. Clin Transpl 2000; 14:19-30.
2. Jain A, Reyes J, Kashyap R, Dodson SF et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000; 232:490-500.
3. Azoulay D, Samuel D, Adam R, Savier E, Karam V, Delvard V, Saliba F, Ichai P, Roche B, Feray C, Vallee JC, Smail A, Castaing D, Bismuth H. Paul Brousse Liver Transplantation: The first 1,500 cases. Clin Transpl 2000; 14:273-280.
4. Shokouh-Amiri MH, Grewal HP, Vera SR, Stratta RJ, Riely CA, Fleckenstein JF, Cowan P, Gaber AO. Eighteen years of experience with adult and pediatric liver transplantation at the University of Tennessee, Memphis. Clin Transpl 2000; 14:255-261.
5. Semhoun-Ducloux S, Ducloux D, Bresson-Hadni S, Becker M, Vanlemmens C, Mantion G, Chalopin J, Miguet J. Systemic hypertension and renal function in long-term liver transplant recipients on cyclosporine. Transplant Proc 2000; 32:449-452.
6. Backman L, Olausson M, Mjornstedt L, Herlenius G, Friman S. Renal function after liver transplantation. Transplant Proc 2001; 33:3442-3443.
7. Reich D, Rothstein K, Manzarbeitia C, Munoz S. Common medical diseases after liver transplantation. Semin Gastrointest Dis 1998; 9:110-125.
8. Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome - experience in 300 patients. Transplantation 1991; 51:428-430.
9. Papadakis MA, Arieff AI. Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study. Am J Med 1987; 82:945-952.
10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
11. Walser M, Drew HH, LaFrance ND. Creatinine measurements often yielded false estimates of progression in chronic renal failure. Kidney Int 1988; 34:412-418.
12. Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995; 59:361-365.
13. Sheiner PA, Magliocca JF, Bodian CA, Kim-Schluger L, Altaca G, Guarrera JV, Emre S, Fishbein TM, Guy SR, Schwartz ME, Miller CM. Long-term medical complications in patients surviving > or - five years after liver transplant. Transplantation 2000; 69:781-789.
14. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: Risk of development and treatment. Transplantation 2001; 72:1934-1939.
15. Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: A retrospective analysis. Transplantation 1998; 66:59-66.
16. Gines P, Arroyo V. Hepatorenal syndrome. J Am Soc Nephrol 1999; 10:1833-1839.
17. Eckhoff DE, McGuire BM, Frenette LR, Contreras JL, Hudson SL, Bynon JS. Tacrolimus (TACROLIMUS) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation 1998; 65:180-187.
18. Giostra E, Roch F, Mentha G. Surveillance du transplanté hépatique. Revue Médicale Suisse Romande 1994; 114:773-779.
19. Rabkin JM, Corless CL, Rosen HR, Olyaei AJ. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am J Surg 2002; 183:595-599.
20. Avdonin PV, Cottet-Maire F, Afanasjeva GV, Loktionova SA, Lhote P, Ruegg UT. Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. Kidney Int 1999; 55:2407-2414.
21. Reuben A. Long-term management of the liver transplant patient: Diabetes, hyperlipidemia, and obesity. Liver Transpl 2001; 7(Suppl. 1):S13-S21.
22. Steinmuller TH, Stockmann M, Bechstein WO, Settmacher U, Jonas S, Neuhaus P. Liver transplantation and diabetes mellitus. Exp Clin Endocrinol Diabetes 2000; 108:401-405.
23. Lerut JP, Ciccarelli O, Mauel E, Gheerardhyn R, Talpe S, Sempoux C, Laterre PF, Roggen FM, Van Leeuw V, Otte JB, Gianello P. Adult liver transplantation and steroid-azathioprine withdrawal in cyclosporine (Sandimmun)-based immunosuppression - 5 year results of a prospective study. Transpl Int 2001; 14:420-428.
24. Miles AM, Sumrani N, Horowitz R, Homel P, Maursky V, Markell MS, Distant DA, Hong JH, Sommer BG, Friedman EA. Diabetes mellitus after renal transplantation. As deleterious as non-transplant-associated diabetes? Transplantation 1998; 65:380-384.
25. Dufer M, Krippeit-Drews P, Lembert N, Idahl LA, Drews G. Diabetogenic effect of Cyclosporin A is mediated by interference with mitochondrial function of pancreatic B-cells. Mol Pharmacol 2001; 60:873-879.
26. Yoshida EM, Buczkowski AK, Sirrs SM, Elliott TG, Scudamore CH, Levin A, Tildesley HD, Landsberg DN. Post-transplant diabetic ketoacidosis - a possible consequence of immunosuppression with calcineurin inhibiting agents: A case series. Transpl Int 2000; 13:69-72.
27. Margarit C, Rimola A, Gonzalez-Pinto I, Cuervas-Mons V, Edo A, Andreu H, Moreno-Gonzalez E, Calleja JL. Efficacy and safety of oral low-dose tacrolimus treatment in liver transplantation. Transpl Int 1998; 11(Suppl. 1):S260-S266.
28. Vannini SD, Mazzola BL, Rodoni L, Truttmann AC, Wermuth B, Bianchetti MG, Ferrari P. Permanently reduced plasma ionized magnesium among renal transplant recipients on cyclosporine. Transpl Int 1999; 12:244-249.
29. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21:1135-1139.
30. Knobler H, Stagnaro-Green A, Wallenstein S, Schwartz M, Roman SH. Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol 1998; 26:30-33.
31. Baid S, Cosimi AB, Farrell ML, Schoenfeld DA, Feng S, Chung RT, Tolkoff-Rubin N, Pascual M. Posttransplant diabetes mellitus in liver transplant recipients: Risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001; 72:1066-1072.
32. Hadziyannis SJ. The spectrum of extrahepatic manifestations in HCV infection. J Viral Hepat 1997; 4:9-28.
33. Charco R, Cantarell C, Vargas V, Capdevila L, Lazaro JL, Hidalgo E, Murio E, Margarit C. Serum cholesterol changes in long-term survivors of liver transplantation: A comparison between cyclosporine and tacrolimus therapy. Liver Transpl Surg 1999; 5:204-208.
34. Gisbert C, Prieto M, Berenguer M, Breto M, Carrasco D, de Juan M, Mir J, Berenguer J. Hyperlipidemia in liver transplant recipients: Prevalence and risk. Liver Transpl Surg 1997; 3:439-442.
35. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002; 73:901-906.
36. Canzanello VJ, Schwartz L, Taler SJ, Textor SC, Wiesner RH, Porayko MK, Krom RA. Evolution of cardiovascular risk after liver transplantation: A comparison of cyclosporine A and tacrolimus (FK506). Liver Transpl Surg 1997; 3:1-9.
37. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation 1997; 63:331-338.
38. Crippin JS. Bone disease after liver transplantation. Liver Transpl 2001;7(11 Suppl. 1):S27-S35.
39. Hamburg SM, Piers DA, van den Berg AP, Slooff MJ, Haagsma EB. Bone mineral density in the long term after liver transplantation. Osteoporos Int 2000; 11:600-606.
40. Monegal A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba MJ, Rimola A, Rodes J, Munoz-Gomez J. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int 2001; 68:83-86.
41. Bonkovsky HL, Hawkins M, Steinberg K, Hersh T, Galambos JT, Henderson JM, Millikan WJ, Galloway JR. Prevalence and prediction of osteopenia in chronic liver disease. Hepatology 1990; 12:273-280.
42. Mentha G, Giostra E, Rubbia L, Huber O, Grossholz M, Romand J, Hadengue A, Morel P. Suivi et résultats de la transplantation hépatique pour cirrhose biliaire primitive. Swiss Surg 1996; 2:116-122.
43. Park KM, Hay JE, Lee SG, Lee YJ, Wiesner RH, Porayko MK, Krom RA. Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine. Transplant Proc 1996; 28:1738-1740.